Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18664120 | Cellular Adjuvants for Viral Infection | May 2024 | February 2025 | Allow | 9 | 1 | 0 | No | No |
| 18664198 | Cellular Adjuvants for Viral Infection | May 2024 | March 2025 | Allow | 10 | 1 | 0 | No | No |
| 18596916 | ESCHERICHIA COLI COMPOSITIONS AND METHODS THEREOF | March 2024 | March 2025 | Allow | 12 | 1 | 0 | No | No |
| 18291870 | METHODS FOR THE REDUCTION OF METHANE PRODUCTION IN RUMINANTS | January 2024 | February 2025 | Allow | 13 | 2 | 1 | No | No |
| 18394580 | COMPOSITIONS AND METHODS FOR GENERATING AN IMMUNE RESPONSE TO TREAT OR PREVENT MALARIA | December 2023 | February 2025 | Allow | 14 | 1 | 0 | No | No |
| 18476731 | Liquid Neurotoxin Formulation Stabilized with Tryptophan or Tyrosine | September 2023 | March 2025 | Allow | 18 | 2 | 0 | No | No |
| 18235530 | METHOD TO MANUFACTURE A STABLE PROTEIN | August 2023 | February 2025 | Abandon | 18 | 0 | 1 | No | No |
| 18223835 | METHODS AND COMPOSITIONS FOR ASSESSING AND TREATING INTRAOCULAR DISEASES AND DISORDERS | July 2023 | April 2025 | Allow | 21 | 1 | 0 | No | No |
| 18221644 | METHOD FOR DETERMINING FACIAL MUSCLE RESPONSES | July 2023 | March 2025 | Allow | 20 | 1 | 0 | No | No |
| 18221835 | MICROORGANISM IDENTIFICATION METHOD | July 2023 | June 2025 | Allow | 23 | 2 | 0 | Yes | Yes |
| 18326511 | TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION | May 2023 | April 2025 | Allow | 23 | 2 | 1 | Yes | No |
| 18318689 | EFFICACIOUS MRNA VACCINES | May 2023 | January 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18136696 | COMPOSITION COMPRISING OIL DROPS | April 2023 | December 2024 | Abandon | 20 | 0 | 1 | No | No |
| 18301121 | APPARATUS, SYSTEMS, AND METHODS FOR DETERMINING THE CONCENTRATION OF MICROORGANISMS AND THE SUSCEPTIBILITY OF MICROORGANISMS TO ANTI-INFECTIVES BASED ON REDOX REACTIONS | April 2023 | December 2024 | Allow | 21 | 2 | 0 | No | No |
| 18301015 | PROMOTER POLYNUCLEOTIDE, SIGNAL POLYPEPTIDE AND USE THEREOF | April 2023 | October 2024 | Allow | 18 | 1 | 1 | Yes | No |
| 18300126 | MICROORGANISMS FOR PLANT PATHOGEN INHIBITION | April 2023 | November 2024 | Allow | 19 | 1 | 0 | Yes | No |
| 18187241 | ENHANCED CHEMILUMINESCENT ENZYME-LINKED IMMUNOSORBENT ASSAY FOR DETECTION OF ANTIBODIES AGAINST BABESIA MICROTI | March 2023 | September 2024 | Allow | 18 | 1 | 0 | No | No |
| 18186588 | PATHOGEN VACCINES AND METHODS OF PRODUCING AND USING THE SAME | March 2023 | December 2024 | Abandon | 21 | 0 | 1 | No | No |
| 18173991 | LIQUID NEUROTOXIN FORMULATION STABILIZED WITH TRYPTOPHAN OR TYROSINE | February 2023 | March 2024 | Abandon | 13 | 2 | 0 | No | No |
| 18103166 | GUT MICROBIOTA AND TREATMENT OF CANCER | January 2023 | February 2025 | Allow | 25 | 1 | 0 | Yes | No |
| 18103082 | PSEUDOMONAS STRAINS AND THEIR METABOLITES TO CONTROL PLANT DISEASES | January 2023 | July 2024 | Allow | 18 | 2 | 0 | No | No |
| 18065689 | METHOD FOR RAPID IN VITRO SYNTHESIS OF GLYCOPROTEINS VIA RECOMBINANT PRODUCTION OF N-GLYCOSYLATED PROTEINS IN PROKARYOTIC CELL LYSATES | December 2022 | April 2025 | Allow | 28 | 2 | 0 | No | No |
| 17922173 | Method to Reduce Tick Population with a Universal Tick Antigen | October 2022 | June 2023 | Allow | 8 | 1 | 1 | No | No |
| 18045914 | HEME-BINDING SMALL PEPTIDE | October 2022 | April 2024 | Allow | 27 | 1 | 1 | No | No |
| 17816318 | LYSIN-ANTIMICROBIAL PEPTIDE (AMP) POLYPEPTIDE CONSTRUCTS, LYSINS, ISOLATED POLYNUCLEOTIDES ENCODING SAME AND USES THEREOF | July 2022 | June 2025 | Abandon | 35 | 2 | 0 | No | No |
| 17858642 | BIOFUSION PROTEINS AS ANTI-MALARIA VACCINES | July 2022 | November 2024 | Abandon | 28 | 0 | 1 | No | No |
| 17857110 | Immunogenic Compositions of Polysaccharide-Protein Pegylated Compounds | July 2022 | January 2025 | Allow | 30 | 2 | 0 | No | No |
| 17852669 | CELL-TARGETING MOLECULES COMPRISING DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT EFFECTORS AND CD8+ T-CELL EPITOPES | June 2022 | March 2025 | Abandon | 32 | 2 | 0 | No | No |
| 17838890 | VACCINE DELIVERY METHOD | June 2022 | August 2024 | Allow | 26 | 1 | 1 | No | No |
| 17806206 | APPARATUS, SYSTEMS, AND METHODS FOR DETERMINING SUSCEPTIBILITY OF MICROORGANISMS TO ANTI-INFECTIVES | June 2022 | January 2025 | Allow | 32 | 2 | 0 | No | No |
| 17832745 | MUCOADHESIVE MICROORGANISM | June 2022 | November 2024 | Allow | 29 | 1 | 1 | Yes | No |
| 17777075 | NEW FORMULATION OF LACTOBACILLUS STRAINS FOR THE TREATMENT AND PREVENTION OF HELICOBACTER PYLORI COLONISATION IN THE UPPER AIRWAYS AND THE DIGESTIVE SYSTEM | May 2022 | March 2025 | Abandon | 34 | 1 | 0 | No | No |
| 17730030 | Pro-Inflammatory and Adjuvant Functions of Toll-Like Receptor 4 Antagonists | April 2022 | April 2024 | Allow | 24 | 1 | 0 | No | No |
| 17729056 | METABOLIC ENGINEERING FOR MICROBIAL PRODUCTION OF TERPENOID PRODUCTS | April 2022 | October 2024 | Allow | 29 | 1 | 0 | Yes | No |
| 17726254 | COMPOSITIONS AND METHODS FOR GENERATING AN IMMUNE RESPONSE TO TREAT OR PREVENT MALARIA | April 2022 | August 2023 | Allow | 16 | 1 | 0 | No | No |
| 17713456 | NMR METHODS AND SYSTEMS FOR THE RAPID DETECTION OF TICK-BORNE PATHOGENS | April 2022 | December 2024 | Abandon | 32 | 1 | 0 | No | No |
| 17763542 | LACTOBACILLUS REUTERI | March 2022 | October 2024 | Allow | 31 | 1 | 0 | Yes | No |
| 17689927 | PROBIOTIC FOR INHIBITING GROWTH OF PROTEUS MIRABILIS, AND FERMENTATION BROTH AND APPLICATION THEREOF | March 2022 | June 2025 | Allow | 39 | 2 | 1 | Yes | No |
| 17684121 | Cellular Adjuvants for Viral Infection | March 2022 | October 2024 | Allow | 32 | 2 | 1 | No | No |
| 17681946 | TREATMENT OF BACTERIAL VAGINOSIS | February 2022 | March 2025 | Abandon | 37 | 1 | 1 | No | No |
| 17638137 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY AND IMMUNE DISEASES | February 2022 | March 2025 | Allow | 37 | 1 | 1 | No | No |
| 17673488 | Lactobacillus Gasseri KBL697 Strain and Use Thereof | February 2022 | August 2023 | Allow | 18 | 1 | 0 | No | No |
| 17590290 | CHIMERIC VACCINE ANTIGENS FOR ANAPLASMOSIS | February 2022 | October 2024 | Allow | 33 | 1 | 0 | No | No |
| 17630107 | FILAMENTOUS FUNGAL EXPRESSION SYSTEM | January 2022 | January 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17553098 | ANTI-MALARIA COMPOSITIONS AND METHODS | December 2021 | October 2024 | Abandon | 34 | 0 | 1 | No | No |
| 17552256 | VACCINE COMPOSITION AGAINST CHLAMYDIACEAE INFECTIONS | December 2021 | August 2023 | Allow | 20 | 1 | 0 | Yes | No |
| 17614876 | METHODS OF TREATING PATIENTS WITH AN IMMUNOGENIC COMPOSITION THAT PROTECTS AGAINST S. PNEUMONIAE SEROTYPE 29 | November 2021 | March 2025 | Abandon | 40 | 2 | 0 | No | No |
| 17612893 | COMPOSITION AND METHOD FOR SPRAY DRYING AN ADJUVANT VACCINE EMULSION | November 2021 | January 2025 | Allow | 38 | 1 | 1 | Yes | No |
| 17525804 | TARGETING OF MELANOCYTES FOR DELIVERING THERAPEUTIC OR DIAGNOSTIC AGENTS USING PROTEIN NANOCAGES | November 2021 | January 2025 | Allow | 39 | 1 | 1 | No | No |
| 17517477 | MUTANT FRAGMENTS OF OSPA AND METHODS AND USES RELATING THERETO | November 2021 | September 2024 | Allow | 34 | 1 | 0 | No | No |
| 17515882 | COMPOSITIONS AND METHODS FOR TREATING THE EYE | November 2021 | August 2023 | Allow | 21 | 1 | 0 | No | No |
| 17507994 | SIGNATURES AND DETERMINANTS FOR DIAGNOSING INFECTIONS AND METHODS OF USE THEREOF | October 2021 | August 2024 | Allow | 34 | 2 | 0 | Yes | No |
| 17494068 | PSEUDOMONAS STRAINS AND THEIR METABOLITES TO CONTROL FISH DISEASES | October 2021 | January 2023 | Allow | 15 | 1 | 0 | Yes | No |
| 17493594 | PSEUDOMONAS STRAINS AND THEIR METABOLITES TO CONTROL PLANT DISEASES | October 2021 | July 2024 | Allow | 33 | 1 | 0 | No | No |
| 17492190 | OPTIMIZED CELL-FREE SYNTHESIS OF INVASION PLASMID ANTIGEN B AND RELATED COMPOSITIONS AND METHODS OF USE | October 2021 | December 2024 | Allow | 38 | 1 | 1 | No | No |
| 17468989 | NEISSERIA MENINGITIDIS VACCINE | September 2021 | March 2023 | Allow | 18 | 0 | 0 | No | No |
| 17420982 | TRYPANOSOMAL VACCINE | July 2021 | June 2024 | Allow | 35 | 1 | 1 | No | No |
| 17304888 | LIQUID NEUROTOXIN FORMULATION STABILIZED WITH TRYPTOPHAN OR TYROSINE | June 2021 | March 2024 | Abandon | 33 | 2 | 0 | No | No |
| 17350683 | MUCOADHESIVE DEVICES FOR THE RELEASE OF PROBIOTICS AND FOR THE MAINTENANCE OF THEIR ENZYME ACTIVITIES | June 2021 | June 2024 | Allow | 36 | 2 | 0 | No | No |
| 17346030 | SYSTEMS AND METHODS FOR ALGAE CULTIVATION USING DIRECT AIR CAPTURE | June 2021 | June 2025 | Allow | 48 | 2 | 0 | No | No |
| 17333255 | ANTIGEN-DRIVEN DETECTION AND TREATMENT OF COCCIDIOIDOMYCOSIS | May 2021 | August 2023 | Allow | 27 | 1 | 0 | No | No |
| 17319004 | BOTULINUM TOXIN CELL BINDING DOMAIN POLYPEPTIDES AND METHODS OF USE FOR TREATMENTS OF FIBROSIS ASSOCIATED DISORDERS | May 2021 | September 2023 | Abandon | 28 | 0 | 1 | No | No |
| 17290566 | METHOD FOR DETERMINING ESCHERICHIA COLI | April 2021 | April 2024 | Allow | 35 | 1 | 0 | Yes | No |
| 17228579 | CELL-TARGETING MOLECULES COMPRISING DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT EFFECTORS AND CD8+ T-CELL EPITOPES | April 2021 | March 2022 | Allow | 11 | 2 | 0 | Yes | No |
| 17228699 | DESIGN AND EXPRESSION OF SARS-COV-2 SPIKE PROTEIN RECEPTOR BINDING DOMAIN IN ATTENUATED SALMONELLA AS A VACCINE | April 2021 | March 2022 | Allow | 11 | 2 | 1 | Yes | No |
| 17224888 | METHODS OF TREATING FUNGAL INFECTIONS | April 2021 | August 2024 | Allow | 40 | 1 | 0 | No | No |
| 17213619 | INDUCTION OF PROTECTIVE IMMUNITY AGAINST ANTIGENS | March 2021 | June 2023 | Allow | 26 | 1 | 0 | No | No |
| 17210965 | PROCESS TO REDUCE ENDOTOXIN IN GELATIN | March 2021 | November 2023 | Abandon | 32 | 1 | 1 | No | No |
| 17207948 | FOOD SAFETY VACCINE TO CONTROL SALMONELLA ENTERICA AND REDUCE CAMPYLOBACTER IN POULTRY | March 2021 | May 2023 | Allow | 26 | 1 | 0 | No | No |
| 17184580 | MICROORGANISMS ENGINEERED FOR MUCONATE PRODUCTION | February 2021 | July 2023 | Allow | 28 | 1 | 1 | Yes | No |
| 17180959 | ESCHERICHIA COLI COMPOSITIONS AND METHODS THEREOF | February 2021 | March 2024 | Abandon | 37 | 3 | 1 | No | No |
| 17170912 | METHOD OF IDENTIFICATION OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS | February 2021 | April 2022 | Allow | 14 | 1 | 1 | Yes | No |
| 17300020 | Method and apparatus for avoiding false positive coliform testing | February 2021 | November 2024 | Abandon | 45 | 2 | 1 | No | Yes |
| 17154536 | Anti-Microbial Immunomodulation | January 2021 | July 2023 | Allow | 30 | 1 | 0 | Yes | No |
| 17152146 | RAPID TEST FOR LYME BACTERIA | January 2021 | August 2023 | Allow | 31 | 1 | 0 | No | No |
| 17127530 | Listeria-Based Compositions Comprising a Peptide Minigene Expression System and Methods of Use Thereof | December 2020 | February 2023 | Allow | 26 | 1 | 0 | No | No |
| 17118391 | COMPOSITION COMPRISING OIL DROPS | December 2020 | April 2023 | Abandon | 28 | 1 | 0 | No | No |
| 17103392 | PROTECTIVE BARRIER COMPOSITIONS AND USES THEREOF | November 2020 | July 2022 | Allow | 20 | 1 | 1 | Yes | No |
| 17102301 | Lactobacillus Gasseri KBL697 Strain and Use Thereof | November 2020 | November 2021 | Allow | 12 | 2 | 0 | Yes | No |
| 16953162 | Methods of Treating Cancer Using Bacteria Expressing c-di-AMP | November 2020 | November 2022 | Allow | 24 | 2 | 1 | Yes | No |
| 17097534 | CHEMOENZYMATIC GLYCOENGINEERING OF ANTIBODIES AND FC FRAGMENTS THEREOF | November 2020 | December 2022 | Allow | 25 | 2 | 1 | No | No |
| 17097371 | BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND A STAPHYLOCOCCUS TARGET ANTIGEN AND A COMPLEMENT COMPONENT AND USES THEREOF | November 2020 | February 2023 | Allow | 27 | 1 | 1 | No | No |
| 16956071 | MAKE-UP COMPOSITION COMPRISING A HYDROLYSATE OF THEOBROMA CACAO L BEANS AND AT LEAST ONE PREBIOTIC AND A PROBIOTIC | November 2020 | April 2025 | Abandon | 58 | 2 | 1 | No | No |
| 17093396 | METHODS FOR INHIBITING BIOFILM FORMATION | November 2020 | March 2023 | Abandon | 29 | 1 | 0 | No | No |
| 17052731 | BIOMARKERS FOR DETECTING MICROBIAL INFECTION | November 2020 | April 2023 | Allow | 29 | 2 | 1 | Yes | No |
| 17077354 | METHOD FOR RAPID IN VITRO SYNTHESIS OF GLYCOPROTEINS VIA RECOMBINANT PRODUCTION OF N-GLYCOSYLATED PROTEINS IN PROKARYOTIC CELL LYSATES | October 2020 | August 2022 | Allow | 22 | 1 | 1 | No | No |
| 17047900 | INHIBITION OF FUNGAL GROWTH BY MANGANESE DEPLETION | October 2020 | March 2023 | Allow | 28 | 2 | 0 | No | No |
| 17070477 | METHOD OF REDUCING EGG CONTAMINATION | October 2020 | March 2023 | Abandon | 29 | 1 | 0 | No | No |
| 17070021 | COMPOSITIONS AND METHODS FOR TREATING DISEASE USING SALMONELLA T3SS EFFECTOR PROTEIN (SipA) | October 2020 | December 2022 | Abandon | 26 | 1 | 0 | No | No |
| 17063540 | PSEUDOMONAS STRAINS AND THEIR METABOLITES TO CONTROL PLANT DISEASES | October 2020 | January 2023 | Allow | 27 | 1 | 1 | Yes | No |
| 17061696 | VACCINE DELIVERY METHOD | October 2020 | August 2022 | Allow | 22 | 2 | 1 | No | No |
| 17061137 | HAEMORRHAGIC DISORDER DUE TO VENTRICULAR ASSIST DEVICE | October 2020 | April 2022 | Allow | 19 | 0 | 1 | Yes | No |
| 17060067 | NEISSERIA MENINGITIDIS COMPOSITION AND METHODS THEREOF | September 2020 | April 2022 | Allow | 18 | 0 | 0 | No | No |
| 17026379 | MUCOADHESIVE MICROORGANISM | September 2020 | March 2022 | Allow | 18 | 0 | 0 | Yes | No |
| 17023133 | A QUANTITATIVE ENZYME-LINKED IMMUNOASSAY (ELISA) TO APPROXIMATE COMPLEMENT FIXING ANTIBODY TITERS IN SERUM FROM PATIENTS WITH COCCIDIOIDOMYCOSIS | September 2020 | June 2022 | Allow | 21 | 1 | 0 | No | No |
| 17018045 | PRO-INFLAMMATORY AND ANTI-CANCER FUNCTIONS OF TOLL-LIKE RECEPTOR 4 ANTAGONISTS | September 2020 | January 2022 | Allow | 60 | 3 | 0 | Yes | No |
| 17018038 | Pro-Inflammatory and Adjuvant Functions of Toll-Like Receptor 4 Antagonists | September 2020 | January 2022 | Allow | 16 | 3 | 0 | Yes | No |
| 17015177 | PATHOGEN VACCINES AND METHODS OF PRODUCING AND USING THE SAME | September 2020 | December 2022 | Allow | 27 | 2 | 1 | No | No |
| 17000590 | IMMUNOGENIC COMPOSITIONS FOR USE IN PNEUMOCOCCAL VACCINES | August 2020 | March 2024 | Abandon | 43 | 5 | 0 | No | No |
| 16996457 | MULTILAYER NANO-CELL | August 2020 | November 2020 | Allow | 3 | 1 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LYONS, MARY M.
With a 7.7% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 8.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner LYONS, MARY M works in Art Unit 1645 and has examined 565 patent applications in our dataset. With an allowance rate of 63.2%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 28 months.
Examiner LYONS, MARY M's allowance rate of 63.2% places them in the 16% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by LYONS, MARY M receive 2.27 office actions before reaching final disposition. This places the examiner in the 77% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by LYONS, MARY M is 28 months. This places the examiner in the 49% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +42.8% benefit to allowance rate for applications examined by LYONS, MARY M. This interview benefit is in the 91% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 19.6% of applications are subsequently allowed. This success rate is in the 13% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 41.0% of cases where such amendments are filed. This entry rate is in the 55% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 75.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 58% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 58.1% of appeals filed. This is in the 26% percentile among all examiners. Of these withdrawals, 88.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 69.4% are granted (fully or in part). This grant rate is in the 87% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.6% of allowed cases (in the 50% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.